Optimization of the treatment with beta-lactam antibiotics in critically ill patients—guidelines from the French Society of Pharmacology and Therapeutics (Société …
R Guilhaumou, S Benaboud, Y Bennis… - Critical Care, 2019 - Springer
Background Beta-lactam antibiotics (βLA) are the most commonly used antibiotics in the
intensive care unit (ICU). ICU patients present many pathophysiological features that cause …
intensive care unit (ICU). ICU patients present many pathophysiological features that cause …
Pharmacokinetics–pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients
RP Veiga, JA Paiva - Critical Care, 2018 - Springer
Antimicrobials are among the most important and commonly prescribed drugs in the
management of critically ill patients and beta-lactams are the most common antibiotic class …
management of critically ill patients and beta-lactams are the most common antibiotic class …
Pharmacokinetic issues for antibiotics in the critically ill patient
JA Roberts, J Lipman - Critical care medicine, 2009 - journals.lww.com
Objective: To discuss the altered pharmacokinetic properties of selected antibiotics in
critically ill patients and to develop basic dose adjustment principles for this patient …
critically ill patients and to develop basic dose adjustment principles for this patient …
What antibiotic exposures are required to suppress the emergence of resistance for gram-negative bacteria? A systematic review
Background The rates of antibiotic resistance in Gram-negative bacteria are increasing. One
method to minimize resistance emergence may be optimization of antibiotic dosing …
method to minimize resistance emergence may be optimization of antibiotic dosing …
Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams
J Gonçalves-Pereira, P Póvoa - Critical Care, 2011 - Springer
Introduction Several reports have shown marked heterogeneity of antibiotic
pharmacokinetics (PK) in patients admitted to ICUs, which might potentially affect outcomes …
pharmacokinetics (PK) in patients admitted to ICUs, which might potentially affect outcomes …
Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy
Pseudomonas aeruginosa and Acinetobacter baumannii are major nosocomial pathogens
worldwide. Both are intrinsically resistant to many drugs and are able to become resistant to …
worldwide. Both are intrinsically resistant to many drugs and are able to become resistant to …
The use of noncarbapenem β-lactams for the treatment of extended-spectrum β-lactamase infections
PD Tamma, J Rodriguez-Baňo - Clinical Infectious Diseases, 2017 - academic.oup.com
The continued rise in infections caused by extended-spectrum β-lactamase (ESBL)–
producing pathogens is recognized globally as one of the most pressing concerns facing the …
producing pathogens is recognized globally as one of the most pressing concerns facing the …
Clinical pharmacokinetics and pharmacodynamics of cefepime
Cefepime is a broad-spectrum fourth-generation cephalosporin with activity against Gram-
positive and Gram-negative pathogens. It is generally administered as an infusion over 30 …
positive and Gram-negative pathogens. It is generally administered as an infusion over 30 …
A systematic review on clinical benefits of continuous administration of β-lactam antibiotics
Objective: The clinical benefits of extended infusion or continuous infusion of β-lactam
antibiotics remain controversial. We systematically reviewed the literature to determine …
antibiotics remain controversial. We systematically reviewed the literature to determine …
Cefepime Therapy for Monomicrobial Bacteremia Caused by Cefepime-Susceptible Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae: MIC …
Background. Extended-spectrum ß-lactamase (ESBL)–producing Enterobacteriaceae
isolates are important clinical pathogens. In addition, the efficacy of cefepime for such …
isolates are important clinical pathogens. In addition, the efficacy of cefepime for such …